Steven K Cheng

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. pmc A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies
    Steven K Cheng
    Center for Management Research in Healthcare, Knight Cancer Institute, Oregon Health and ScienceUniversity, 3303 Bond Avenue, Portland, OR 97239, USA
    Clin Cancer Res 16:5557-63. 2010
  2. pmc Phase III clinical trial development: a process of chutes and ladders
    David M Dilts
    Knight Cancer Institute, Center for Management Research in Healthcare, Division of Management, School of Medicine, Oregon Health and Science University, 3303 SW Bond Avenue, Portland, OR 97239, USA
    Clin Cancer Res 16:5381-9. 2010
  3. doi request reprint The importance of doing trials right while doing the right trials
    David M Dilts
    Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Clin Cancer Res 18:3-5. 2012
  4. pmc Steps and time to process clinical trials at the Cancer Therapy Evaluation Program
    David M Dilts
    Center for Management Research in Healthcare, Vanderbilt University, Nashville, TN 37235 1518, USA
    J Clin Oncol 27:1761-6. 2009
  5. pmc Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials
    Steven K Cheng
    Center for Management Research in Healthcare, Oregon Health and Science University, Portland, Oregon, USA
    Clin Cancer Res 17:1947-55. 2011
  6. pmc The prevalence and economic impact of low-enrolling clinical studies at an academic medical center
    Darlene R Kitterman
    Investigator Support and Integration Services, Oregon Clinical and Translational Research Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
    Acad Med 86:1360-6. 2011
  7. ncbi request reprint Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B
    David M Dilts
    Center for Management Research in Healthcare, Vanderbilt University, Nashville, TN, USA
    J Clin Oncol 24:4553-7. 2006

Detail Information

Publications7

  1. pmc A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies
    Steven K Cheng
    Center for Management Research in Healthcare, Knight Cancer Institute, Oregon Health and ScienceUniversity, 3303 Bond Avenue, Portland, OR 97239, USA
    Clin Cancer Res 16:5557-63. 2010
    ..Postactivation barriers to oncology clinical trial accruals are well documented; however, potential barriers prior to trial opening are not. We investigate one such barrier: trial development time...
  2. pmc Phase III clinical trial development: a process of chutes and ladders
    David M Dilts
    Knight Cancer Institute, Center for Management Research in Healthcare, Division of Management, School of Medicine, Oregon Health and Science University, 3303 SW Bond Avenue, Portland, OR 97239, USA
    Clin Cancer Res 16:5381-9. 2010
    ....
  3. doi request reprint The importance of doing trials right while doing the right trials
    David M Dilts
    Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Clin Cancer Res 18:3-5. 2012
    ..It is time to assess the impact of such trials on meeting the critical needs of cancer patients by establishing effectiveness measures (i.e., doing the right trials)...
  4. pmc Steps and time to process clinical trials at the Cancer Therapy Evaluation Program
    David M Dilts
    Center for Management Research in Healthcare, Vanderbilt University, Nashville, TN 37235 1518, USA
    J Clin Oncol 27:1761-6. 2009
    ..To examine the processes and document the calendar time required for the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) and Central Institutional Review Board (CIRB) to evaluate and approve phase III clinical trials...
  5. pmc Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials
    Steven K Cheng
    Center for Management Research in Healthcare, Oregon Health and Science University, Portland, Oregon, USA
    Clin Cancer Res 17:1947-55. 2011
    ..It is critical to identify early predictors of eventual study accrual achievement...
  6. pmc The prevalence and economic impact of low-enrolling clinical studies at an academic medical center
    Darlene R Kitterman
    Investigator Support and Integration Services, Oregon Clinical and Translational Research Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
    Acad Med 86:1360-6. 2011
    ..The authors assessed the prevalence and associated economic impact of low-enrolling clinical studies at a single academic medical center...
  7. ncbi request reprint Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B
    David M Dilts
    Center for Management Research in Healthcare, Vanderbilt University, Nashville, TN, USA
    J Clin Oncol 24:4553-7. 2006
    ..We examine the processes and document the calendar time required to activate such studies opened by the Cancer and Leukemia Group B (CALGB)...